| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2578020 | Revista del Laboratorio Clínico | 2016 | 4 Pages |
Abstract
With conventional treatments median survival was 3 years, which has increased to 7 years with new treatments. Leukemized MCL prognosis is lower than in a ganglion forms without peripheral expression.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Aleix Borja Fabregat Bolufer, Pedro Luis Estela Burriel, Marta Valero Núñez,